BlackRock’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-4,263,241
| Closed | -$164M | – | 5602 |
|
|
2023
Q2 | $164M | Buy |
4,263,241
+320,702
| +8% | +$8.24M | ﹤0.01% | 1722 |
|
|
2023
Q1 | $91.3M | Sell |
3,942,539
-12,202
| -0.3% | -$291K | ﹤0.01% | 2074 |
|
|
2022
Q4 | $104M | Buy |
3,954,741
+303,442
| +8% | +$6.72M | ﹤0.01% | 1969 |
|
|
2022
Q3 | $71.8M | Buy |
3,651,299
+319,169
| +10% | +$6.4M | ﹤0.01% | 2173 |
|
|
2022
Q2 | $58.3M | Buy |
3,332,130
+277,133
| +9% | +$4.35M | ﹤0.01% | 2382 |
|
|
2022
Q1 | $50M | Buy |
3,054,997
+67,066
| +2% | +$912K | ﹤0.01% | 2591 |
|
|
2021
Q4 | $48.7M | Buy |
2,987,931
+450,705
| +18% | +$6.42M | ﹤0.01% | 2681 |
|
|
2021
Q3 | $32.4M | Buy |
2,537,226
+66,757
| +3% | +$879K | ﹤0.01% | 2952 |
|
|
2021
Q2 | $34.9M | Buy |
2,470,469
+1,063,133
| +76% | +$17M | ﹤0.01% | 2938 |
|
|
2021
Q1 | $21.9M | Sell |
1,407,336
-946
| -0.1% | -$15.4K | ﹤0.01% | 3141 |
|
|
2020
Q4 | $22.3M | Buy |
1,408,282
+530,303
| +60% | +$8M | ﹤0.01% | 2938 |
|
|
2020
Q3 | $10.7M | Sell |
877,979
-19,818
| -2% | -$266K | ﹤0.01% | 3192 |
|
|
2020
Q2 | $10.4M | Buy |
897,797
+25,615
| +3% | +$353K | ﹤0.01% | 3165 |
|
|
2020
Q1 | $11.9M | Sell |
872,182
-809
| -0.1% | -$9.57K | ﹤0.01% | 2904 |
|
|
2019
Q4 | $5.15M | Sell |
872,991
-186,536
| -18% | -$1.01M | ﹤0.01% | 3488 |
|
|
2019
Q3 | $5.62M | Buy |
1,059,527
+14,354
| +1% | +$95.3K | ﹤0.01% | 3454 |
|
|
2019
Q2 | $8.05M | Buy |
1,045,173
+44,002
| +4% | +$670K | ﹤0.01% | 3351 |
|
|
2019
Q1 | $19.9M | Sell |
1,001,171
-63,758
| -6% | -$1.11M | ﹤0.01% | 2755 |
|
|
2018
Q4 | $14.1M | Buy |
1,064,929
+40,680
| +4% | +$813K | ﹤0.01% | 2916 |
|
|
2018
Q3 | $37.6M | Buy |
1,024,249
+82,944
| +9% | +$2.66M | ﹤0.01% | 2535 |
|
|
2018
Q2 | $32.9M | Buy |
941,305
+230,660
| +32% | +$8.84M | ﹤0.01% | 2594 |
|
|
2018
Q1 | $33M | Sell |
710,645
-9,599
| -1% | -$351K | ﹤0.01% | 2498 |
|
|
2017
Q4 | $27M | Sell |
720,244
-11,600
| -2% | -$506K | ﹤0.01% | 2627 |
|
|
2017
Q3 | $39M | Buy |
731,844
+53,510
| +8% | +$3.18M | ﹤0.01% | 2434 |
|
|
2017
Q2 | $38.7M | Buy |
678,334
+45,527
| +7% | +$2.29M | ﹤0.01% | 2410 |
|
|
2017
Q1 | $34M | Buy |
632,807
+632,016
| +79,901% | +$35.7M | ﹤0.01% | 2443 |
|
|
2016
Q4 | $45K | Sell |
791
-2,133
| -73% | -$129K | ﹤0.01% | 2990 |
|
|
2016
Q3 | $181K | Buy |
2,924
+404
| +16% | +$28.6K | ﹤0.01% | 2229 |
|
|
2016
Q2 | $142K | Buy |
2,520
+2,391
| +1,853% | +$145K | ﹤0.01% | 2304 |
|
|
2016
Q1 | $8K | Buy |
129
+91
| +239% | +$7.36K | ﹤0.01% | 3250 |
|
|
2015
Q4 | $5K | Hold |
38
| – | – | ﹤0.01% | 3173 |
|
|
2015
Q3 | $4K | Hold |
38
| – | – | ﹤0.01% | 3093 |
|
|
2015
Q2 | $6K | Buy |
+38
| New | +$6.28K | ﹤0.01% | 3088 |
|
BlackRock's KDNY Position: Q3 2023 in Review
BlackRock sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 4,263,241 shares — an estimated $164M sold.
BlackRock first reported a position in KDNY in Q2 2015 and held it in 33 quarters. The position peaked at $164M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- BlackRock reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- BlackRock sold 4,263,241 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $164M.
- BlackRock first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 33 quarters.
- BlackRock's Chinook Therapeutics, Inc. Common Stock position peaked at $164M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on BlackRock's 13F filing for Q3 2023, filed 13 Nov 2023.